Outcome of Board Meeting held on May 07, 2026
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts more than Nifty Microcap 250 and 1.4 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Thyrocare Technologies' Board approved the audited standalone and consolidated financial results for FY ended March 31, 2026, reporting standalone net profit of Rs. 148.81 Crores (up from Rs. 95.78 Crores in the prior year). The Board recommended a final dividend of Rs. 7 per equity share (bringing total dividend to Rs. 9.33 per share post-bonus adjustment for FY26). The Board appointed Price Waterhouse Chartered Accountants LLP as new Statutory Auditors for a 5-year term from the 26th AGM, replacing MSKA & Associates LLP who completed their term. Mr. Rahul Franklin Guha was re-appointed as Chairman, Managing Director & CEO for another 5 years from May 4, 2027. Two new Non-Executive, Non-Independent Directors were appointed — Mr. Uday Patel Kadam and Mr. Gaurav Verma — while two existing directors, Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah, resigned citing pre-occupation and other commitments, effective close of business on May 7, 2026. The Board also approved investment up to Rs. 5.50 Crores in Think Health Diagnostics Private Limited (a wholly owned subsidiary) and alteration of the Company's MOA to align with the Companies Act, 2013 and expand the objects clause to cover a wider range of healthcare and diagnostics activities.
The resignation of two directors on the same day as two appointments suggests a board reshuffle, though both departures were attributed to personal commitments with no material reasons reported. Shareholders can expect steady dividends and improved profitability for FY26. The MOA alteration signals potential business expansion beyond core diagnostics.